Mutations found in cell‐free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis. Issue 10 (12th September 2019)

• Record Type: Journal Article
• Authors: Suehara, Yasuhito; Sakata‐Yanagimoto, Mamiko; Hattori, Keiichiro; Kusakabe, Manabu; Nanmoku, Toru; Sato, Taiki; Noguchi, Masayuki; Chiba, Shigeru
• Is Part Of: Cancer science. Volume 110:Issue 10(2019)
• Page Start: 3375
• Page End: 3381
• Publication Date: 2019-09-12
• Subjects: B‐cell lymphoma -- cell‐free DNA -- circulating tumor DNA -- clonal hematopoiesis of indeterminate potential -- TP53; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.14176
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: Cell‐free DNA (cfDNA) analysis to detect circulating tumor DNA has been focused on monitoring malignant lymphomas. However, clonal hematopoiesis of indeterminate potential (CHIP)‐associated mutations can also be detected by cfDNA analysis. Our aim is to investigate the origin of mutations detected in cfDNA among B‐cell lymphoma patients. MYD88 / CD79B, DNMT3A, and TP53 were chosen as genes of interest, representing each of the following categories: lymphoma driver genes, CHIP‐related genes, and genes shared between lymphoma and CHIP. Seventy‐five B‐cell lymphoma patients were included in this retrospective study. Serum cfDNAs at time of complete metabolic response (CMR) were sequenced for TP53 (N = 75) and DNMT3A (N = 49). MYD88 p.L265P and CD79B p.Y196C/H mutations were analyzed in diffuse large B‐cell lymphoma (DLBCL) patients whose tumor samples were available (N = 29). Two and seven mutations in TP53 and DNMT3A, respectively, were detected in cfDNA at CMR. These mutations were detected in either bone marrow mononuclear cells (BMMC) or PBMC. Although four DNMT3A mutations were also detected in tumors, median variant allele frequencies in the tumors (<1.0%) were significantly lower than those in both BMMC (6.1%) and serum (5.2%) obtained before the therapy. Conversely, five MYD88 and three CD79B mutations detected in tumors were confirmed in cfDNA before therapy, but not in BMMC nor in cfDNA at CMR. Thus, all TP53 and DNMT3A mutations detected in cfDNA at remission seemed to originate from CHIP rather than from residual disease. Results of liquid biopsy should be carefully interpreted, especially in genes shared between lymphomas and CHIP. Abstract : Mutations detected by liquid biopsy can derive not only from tumors but also from clonal hematopoiesis in patients with lymphomas. Results of liquid biopsy should be carefully interpreted because its significance is different according to the origin of the mutations.